# The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

> **NCT06984159** · PHASE3 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 137 (actual)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** Leuprolide Injectable Emulsion (CAMCEVI®)

## Key facts

- **NCT ID:** NCT06984159
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-12
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-04-24
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06984159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06984159, "The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06984159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*